Last reviewed · How we verify

NCT05248464

Distress Related to the Feeling of Loss of Dignity in Patients With Rheumatic Diseases

Status unknown Last updated 6 April 2022
What this trial tests

trial testing The Patient Dignity Inventory instrument (PDI) in Rheumatic Diseases in 309 participants. Status unknown.

Timeline
1 March 2022
Primary endpoint
1 March 2023
1 March 2023

Quick facts

Lead sponsorNational Institute of Medical Sciences and Nutrition, Salvador Zubiran
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment309
Start date1 March 2022
Primary completion1 March 2023
Estimated completion1 March 2023
Sites1 location across Mexico

Drugs / interventions tested

Conditions studied

Sponsor

National Institute of Medical Sciences and Nutrition, Salvador Zubiran

Who can join

Adults 18 to 99, any sex, with Rheumatic Diseases or Dignity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Rheumatic diseases (RD) are an important group of different clinical entities and specific diseases that affect a significant proportion of the world population. In Mexico, the RD have a relevant representation in the adult population. Dignity is a construct characterized by the representation of the self, of the self from others' point of view, and of the interaction of the individual with the environment and social context. Living with a chronic illness can threaten experiences of dignity for the sick person and their families. Various studies have demonstrated the direct impact of the disease on dignity in terms of physical and psychological symptoms and loss of function. Some efforts have been made to operationalize the concept of perceived dignity in the context of chronic diseases The perceived dignity of patients and the distress related to the feeling of loss of dignity (DRFLD) are outcomes that the patient can report and that the doctors can evaluate to be incorporated into the considerations of comprehensive care. Both outcomes are closely related, perceived dignity refers to a complex phenomenon, while distress related to the feeling of loss of dignity identifies those patients with a perceived dignity compromise of such magnitude that it generates anguish.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Perceived dignity is an unrecognized source of emotional distress in patients with rheumatic diseases: Results from the validation of the Mexican version of the Patient Dignity Inventory.
    Pascual-Ramos V, Contreras-Yáñez I, Cuevas-Montoya M, Guaracha-Basáñez GA, et al · · 2023 · cited 4× · PMID 37540659 · DOI 10.1371/journal.pone.0289315
  2. The impact of underlying RMD diagnosis on dignity landscape in patients with systemic lupus erythematosus, rheumatoid arthritis, and systemic sclerosis.
    Pascual-Ramos V, Contreras-Yáñez I, Cuevas-Montoya M, Guaracha-Basáñez G, et al · · 2025 · PMID 40696675 · DOI 10.1097/md.0000000000043303

Verify or expand the search:

Other recruiting trials for Rheumatic Diseases

Currently open trials in the same condition.

Other National Institute of Medical Sciences and Nutrition, Salvador Zubiran trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05248464.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing